We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+18.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$445M
AUM Growth
+$21.4M
Cap. Flow
-$18.8M
Cap. Flow %
-4.22%
Top 10 Hldgs %
46.96%
Holding
84
New
14
Increased
27
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$15.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$9.12M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.93M
4
VCYT icon
Veracyte
VCYT
+$5.3M
5
PCVX icon
Vaxcyte
PCVX
+$5.23M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$16.6M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.83M
3
CLDX icon
Celldex Therapeutics
CLDX
+$8.76M
4
NUVL
Nuvalent
NUVL
+$7.82M
5
URGN icon
UroGen Pharma
URGN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADCT icon
26
ADC Therapeutics
ADCT
$140M
$5.65M 1.27%
1,795,080
+26,310
+1% +$83K
GOSS icon
27
Gossamer Bio
GOSS
$101M
$5.57M 1.25%
5,645,352
+145,352
+3% +$140K
OLMA icon
28
Olema Pharmaceuticals
OLMA
$977M
$5.43M 1.22%
455,082
-91,781
-17% -$1.17M
BBOT
29
BridgeBio Oncology
BBOT
$660M
$5.36M 1.2%
513,369
+13,369
+3% +$138K
ABVX
30
Abivax
ABVX
$10.4B
$5.32M 1.19%
461,660
+5,860
+1% +$70.2K
WVE icon
31
Wave Life Sciences
WVE
$1.12B
$5.15M 1.16%
627,552
+132,081
+27% +$790K
IRON icon
32
Disc Medicine
IRON
$2.81B
$5.1M 1.15%
103,862
+2,675
+3% +$126K
BHVN icon
33
Biohaven
BHVN
$2.02B
$4.98M 1.12%
99,566
-434
-0.4% -$16.9K
CLDX icon
34
Celldex Therapeutics
CLDX
$2.94B
$4.93M 1.11%
145,000
-229,910
-61% -$8.76M
LBPH
35
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$4.14M 0.93%
124,353
+1,504
+1% +$51.8K
BIIB icon
36
Biogen
BIIB
$30.9B
$3.87M 0.87%
19,940
+575
+3% +$120K
PRAX icon
37
Praxis Precision Medicines
PRAX
$8.11B
$3.86M 0.87%
67,045
-251
-0.4% -$13.6K
MODD icon
38
Modular Medical
MODD
$11.3M
$3.24M 0.73%
48,000
+18,000
+60% +$970K
SLDB icon
39
Solid Biosciences
SLDB
$792M
$3.19M 0.72%
457,739
-15,256
-3% -$124K
BNTX icon
40
BioNTech
BNTX
$23.5B
$3.1M 0.7%
+26,083
New +$2.4M
GPCR icon
41
Structure Therapeutics
GPCR
$3.37B
$3.09M 0.7%
70,516
– –
MRSN
42
DELISTED
Mersana Therapeutics
MRSN
$3M 0.67%
63,431
-36,592
-37% -$1.61M
RLAY icon
43
Relay Therapeutics
RLAY
$4B
$2.97M 0.67%
+419,242
New +$3.13M
TELA icon
44
TELA Bio
TELA
$30.3M
$2.85M 0.64%
1,124,928
+124,928
+12% +$444K
CGEN icon
45
Compugen
CGEN
$212M
$2.72M 0.61%
1,501,113
– –
CERS icon
46
Cerus
CERS
$575M
$2.6M 0.58%
1,495,329
+29,585
+2% +$62.1K
ZVRA icon
47
Zevra Therapeutics
ZVRA
$578M
$2.43M 0.55%
+350,000
New +$2.38M
CATX icon
48
Perspective Therapeutics
CATX
$327M
$2.24M 0.5%
167,986
-92,023
-35% -$1.22M
BIOA
49
BioAge Labs
BIOA
$986M
$2.08M 0.47%
+100,000
New +$2M
UNCY icon
50
Unicycive Therapeutics
UNCY
$130M
$1.63M 0.37%
+400,000
New +$1.61M
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Silverarc Capital Management held 84 positions worth $445M, up 5.1% from $424M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Silverarc Capital Management withdrew a net $18.8M in Q3 2024, closing 13 positions and reducing 18 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $16.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Centessa Pharmaceuticals worth $11.9M.

  • Silverarc Capital Management's largest Q3 2024 buy was Centessa Pharmaceuticals: 744,592 shares worth $11.9M.
  • Silverarc Capital Management added most to Insmed in Q3 2024, an estimated $15.3M increase.
  • Silverarc Capital Management's biggest Q3 2024 reduction was Celldex Therapeutics, cutting an estimated $8.76M.
  • Silverarc Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $16.6M.
  • Silverarc Capital Management's ten largest holdings make up 47% of its $445M portfolio in Q3 2024.
  • Silverarc Capital Management opened 14 new positions and closed 13 in Q3 2024.
  • Silverarc Capital Management's portfolio value rose 5.1% quarter-over-quarter to $445M.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.